Bronchiectasis Clinical Trials

Find Bronchiectasis Clinical Trials Near You

A Sequential, Phase 1a/1b, Double-blind, 2-part Study to Investigate the Safety, Tolerability, Microbiological Response, and Pharmacokinetics of Rev-56 for Inhalation Compared With Placebo in Healthy Adult Participants and Adult Non-cystic Fibrosis Bronchiectasis (NCFB) Patients With Chronic Pseudomonas Aeruginosa

Status: Active_not_recruiting
Location: See location...
Intervention Type: Drug, Combination product
Study Type: Interventional
Study Phase: Phase 1
SUMMARY

This is a Phase 1a/1b study to test the safety, tolerability, microbiological response, and pharmacokinetics of inhaled Rev-56 compared to placebo in adult healthy participants and non-cystic fibrosis bronchiectasis (NCFB) patients with P. aeruginosa, respectively. Phase 1a (Part A) will evaluate single doses of inhaled Rev-56 in adult healthy participants and includes up to 5 cohorts. Eligible participants will be randomized to active treatment or placebo in a 3:1 randomization scheme. Phase 1b (Part B) will evaluate the safety, tolerability, microbiological response, and pharmacokinetics of multiple doses of inhaled Rev-56 in NCFB patients with P. aeruginosa and includes 2 cohorts evaluating once daily dosing and twice daily dosing, respectively. Eligible participants will be randomized to active treatment or placebo in a 2:1 randomization scheme.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 80
Healthy Volunteers: t
View:

• Healthy male and female participants aged 18 to 55 years, inclusive

• Body mass index \> 18 to ≤ 32 kg/m\^2

• Forced expiratory volume in 1 second (FEV1) ≥ 80%

• Creatinine clearance ≥ 90 mL/min

• Normal laboratory values and physical exam at screening, or Grade 1 abnormalities that are not clinically significant

• Male and female NCFB patients aged 18 to 80 years, inclusive

• Bronchiectasis confirmed by prior computerized tomography (CT) scan

• Chronic P. aeruginosa infection (≥ 2 positive cultures within prior 12 months)

• Screening sputum culture positive for P. aeruginosa at ≥ 10\^4 CFU/mL

• FEV1 ≥ 50% (post bronchodilator)

Locations
United States
Florida
Syneos Health Miami
Miami
Time Frame
Start Date: 2026-07-13
Completion Date: 2027-07
Participants
Target number of participants: 64
Treatments
Experimental: Cohort 1a
3.5 mg Rev-56 or placebo single dose
Experimental: Cohort 2a
7 mg Rev-56 or placebo single dose
Experimental: Cohort 3a
14 mg Rev-56 or placebo single dose
Experimental: Cohort 4a
28 mg Rev-56 or placebo single dose
Experimental: Optional Cohort 5a
≤56 mg Rev-56 or placebo single dose
Experimental: Cohort 1b
≤28 mg Rev-56 or placebo once daily for 7 days
Experimental: Cohort 2b
≤28 mg Rev-56 or placebo twice daily for 7 days
Related Therapeutic Areas
Sponsors
Collaborators: National Institute of Allergy and Infectious Diseases (NIAID)
Leads: Revagenix, Inc.

This content was sourced from clinicaltrials.gov

Similar Clinical Trials